CA2313805A1 - Method for reducing susceptibility to hiv infection - Google Patents

Method for reducing susceptibility to hiv infection Download PDF

Info

Publication number
CA2313805A1
CA2313805A1 CA002313805A CA2313805A CA2313805A1 CA 2313805 A1 CA2313805 A1 CA 2313805A1 CA 002313805 A CA002313805 A CA 002313805A CA 2313805 A CA2313805 A CA 2313805A CA 2313805 A1 CA2313805 A1 CA 2313805A1
Authority
CA
Canada
Prior art keywords
cells
cd40l
cell
hiv
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002313805A
Other languages
French (fr)
Inventor
Elaine K. Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2313805A1 publication Critical patent/CA2313805A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2013IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2086IL-13 to IL-16
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

There is disclosed a method of reducing susceptibility of cells to infection by a retrovirus, comprising contacting the cells with an amount of a CD40 binding protein effective to reduce the expression of the chemokine receptor CCR5, and/or induce a post-entry block of the replication of the retrovirus.
The method is useful in treating individuals infected with, or at risk of being infected with, HIV. CD40 binding proteins include CD40 ligand, monoclonal antibodies that specifically bind CD40, and combinations thereof.
CD40 binding proteins may also be used in combination with other cytokines, including GM-CSF, IL-2 and IL-15.

Description

wo ~r~ai3s pc~rms9sn~oos s TITLE
METHOD FOR REDUCINQ~ SUSCEP'TTBILITY TO HIV INFF,C1'iON
TECHNIC~IL,~j~~ D OF THENT, ION
The present invention relates to a method of reducing the susceptibility of a cell to infection by human immunodeficiency virus (HIV), comprising contacting the cell with an effective amount of a biologically active CD40 binding protein.
BACKGROUND OF T'~ I'Cf VENTION
The cluster of differentiation antigen CD4 was originally identified as a receptor used by human immunodeficiency virus (HIV) in binding to cells (Dalgleish et al., Nature 312:763; 1984). Subsequent to that time, it became clear that additional molecules, 2o referred to as co-receptors, were necessary for viral entry into cells (Maddon et al., Cell 47:333; 1986). Eventually, it became clear that certain chemokine receptors could act as co-receptors for HIV. Among these is CCRS, a chemokine receptor that binds MIPla, MIP1B and RANT'ES. A CCR5 antagonist that is an analog of the chemokine RANTES
has been shown to block.HIV infection, and may be useful in preventing HIV
infection (Simmons et al., Science 276:276;1997).
CD40L is a type II membrane polypeptide having an extracellular region at its C-terminus, a transmembrane region and an intracellular region at its N-terminus. Soluble CD40L comprises an extracellular region of CD40L (amino acid 47 to amino acid 261 of human CD40L) or a fragment thereof. CD40L biological activity is mediated by binding of the extracellular region of CD40L with CD40, and includes B cell proliferation and induction of antibody secretion (including IgE secretion). Soluble, oligomeric has been shown to induce production of the chemokines MIP-la, MIP-1B and RANTES
from monocytesJmacmphages.
Accordingly, CD40L (and other CD40-binding proteins that bind CD40 and trigger secretion of these chemokines) may act to reduce the susceptibility of cells to HIV
infection by stimulating the production of chemokines that bind to CCRS, and thereby WO 99/32138 p~NSggn'~
prevent HIV from using the CCRS as a co-receptor. However, prior to the instant invention, it was not known that CD40 binding proteins such as CD44L could down regulate CCRS expression, and render macrophages not permissive for HIV
infection.
to ~.T~ABY~.,ii~~Z~~U1~
A recombinant, soluble form of CD40L causes monocytes to down-rcgulate surface expression of CCRS, and induces expression of the chemokines MIP-la, and RANTES. CD40L-stimulated monocyte..derived macrophages are not permissive for HIV-1 infection, possibly to down regulation of CCRS, andlor a post-entry block of viral replication. Blood monocytes contacted with CD40L are less likely to become infected with macrophage-tropic virus and may protect bystander cells by producing chemolcines that antagonize macrophage-tropic HIV-1 replication in monocytes as well as T
cells.
The present invention relates to a method of reducing the susceptibility of a cell to HIV infection, comprising contacting the cell with an amount of a CD40 binding protein 2o effective to down-regulate CCRS expression by the cell, or to render the cell non permissive for HIV infection. CD40 binding proteins are pharmaceutical compositions capable of binding CD40 and transducing a biological signal. CD40 binding proteins are selected from the group consisting of CD40 ligand, monoclonal antibodies that specifically bind CD44, and combinations thereof.
Figure 1 presents results that indicate that CD40L, alone or in combination with GM-CSF, induces production of various chemokines by monocytes.
Figure 2 presents results that indicate that CD40L inhibits the replication of a 3o JRFL pseudotyped retrovirus.
The present invention relates to a method of reducing the susceptibility of a cell to HIV infection, comprising contacting the cell with a CD40 binding protein that is capable of binding CD40 and transmitting a biological signal to a CD40-expressing cell. The binding of the CD40 binding protein causes the down-regulation of CCRS, a chemokine wo ~r~zi3s Pc-ricrs9sn~oos receptor, which decreases the amount of CCRS available to act as a co-neceptor for HIV
entry into the cell. Alternatively, or in addition to this effect, CD40 binding proteins may cause a post-entry block of HIV replication. CD40 binding proteins will also stimulate the cells to secrete chemokines, which may protect bystander cells from HIV
infection by antagonizing the use of chemokine receptors as viral co-receptors.
to The findings described herein also provide data to enable a method of reducing the susceptibility of an individual to HIV infection, by administering a pharmaceutical composition comprising a substance with CD40 binding protein activity to the individual.
Human CD40 antigen (CD40) is a peptide of 277 amino acids having a molecular weight of 30,600 (Stamenkovic et al., EMBO J. 8:1403, 1989). A cDNA encoding human CD40 was isolated from a cDNA library prepared from Burkitt lymphoma cell line Raji. The putative protein encoded by the CD40 cDNA contains a putative leader sequence, traps-membrane domain and a number of other features common to membrane-bound receptor proteins. CD40 has been found to be expressed on B lymphocytes, epithelial cells and some carcinoma cell lines.
CD40 is a member of the tumor necrosis factor (11VF)/nerve growth factor (NGF) receptor family, which is defined by the presence of cysteine-rich motifs in the extracellular region (Smith et al., Science 248:1019, 1990; Mallett and Barclay, Immunology Today 12:220; 1991). This family includes the lymphocyte antigen CD27, CD30 (an antigen found on Hodgkin's lymphoma and Reed-Sternberg cells), two receptors for TNF, a marine pmtein referred to as 4-1BB, rat OX40 antigen, NGF
receptor, and Fas antigen. CD40 is functionally expressed on monocytes/macrophages, B
cells, lymphoma cells, carcinoma cells, dendritic cells, and vascular endothelial cells.
3o CD40 may be detected on the surface of a cell by any one of several means known in the art. For example, an antibody specific for CD40 may be used in a fluorescence-activated cell sorting technique to determine whether cells express CD40.
Other methods of detecting cell surface molecules are also useful in detecting CD40.
C~0 Monoclonal Antibodies Monoclonal antibodies directed against the CD40 surface antigen (CD40 mAb) have been shown to mediate various biological activities on human B cells. For example, CD40 mAb induce homotypic and heterotypic adhesion (Barrett et al., J.
1»rmunol.
146:1722, 1991; Gordon et al., J. Immunol. 140:1425, 1988), and increase cell size (Gordon et al., J. Immunol. 140:1425, 1988; Valle et ai., Eur. J. Immunol.
19:1463, 1989).
CD40 mAb also induce proliferation of B cells activated with anti-IgM, CD20 mAb, or phorbol ester alone (Clark and Lodbetter, Proc. Nail. Acad Sci. USA 83:4494, 1986;
Gordon et al., Leukocyte Typing III; A.J. McMichael ed. Oxford University Press.
Oxford, p. 426; Paulie et al., J. Immunol. 142:590, 1989) or in concert with IL-4 (Vane et al., Eur. J. Immunol. 19:1463, 1989; Gordon et al., Eur. J. Immunol. 17:1535, 1987), and produce IgE (Jabara et al., J. ~Fxp. Med 172:1861, 1990; Gascan et al., J.
Immunol. 147:8, 1991), IgG, and IgM (Gascan et al., J. Immunol. 147:8, 1991) from IL-4-stimulated T
cell-depleted cultures.
In addition, C1J40 mAb have been reported to enhance IL-4-mediated soluble 2o CD23/Fc~ release from B cells (Gordon and Guy, Immunol. Today 8:339, 1987;
Cairns et al., Eur. J. Immunol. 18:349, 1988) and to promote B cell production of IL-6 (Clark and Shu, J. Immunol. 145:1400, 1990). Recently, in the presence of CDw32+
adherent cells, human B cell lines have been generated from primary B cell populations with IL-4 and CD40 mAb (Banchereau et al., Science 241:70, 1991). Furthermore, germinal center centrocytes can be prevented from undergoing apoptosis if they are activated through CD40 and/or receptors for antigen {Liu et al., Nature 342:929, 1989).
Each of the above publications describes CD40 mAb that stimulate a biological activity of B cells.
U.S.S.N. 08/130, 541, filed October 1, 1993, the relevant disclosure of which is 3o incorporated by reference, discloses two monoclonal antibodies that specifically bind Cl?40, referred to as hCD40m2 and hCD40m3. Unlike other CD40 mAb, hCD40m2 (ATCC HB 11459) and hCD40m3 bind CD40 and inhibit binding of CD40 to cells that constitutiveiy express CD40L. Greater than 95°k inhibition of binding was observed with hCD40m2 or with CD40 mAb M3, at concentrations as low as 12.5pg/ml, as compared to irrelevant IgG or a control C1740 mAb, 628.5. hCD40m2 was also able to inhibit CD40L-induced TNF-a production.
wo ~r~m3s rcrms~n~oos Additional CD40 monoclonal antibodies may be generated using conventional techniques (see U.S. Patcnt Nos. RE 32;011, 4,902,614, 4;543,439, and 4,411,993 which are incorporated herein by reference; see also Monoclonal Antibodies, Hybridomas: A
New Dimension in Biological Analyses, Plenum Press, Kennett, McKearn, and Bechtol (cds.), 1980, and Antibodies: A Laboratory Manual, Harlow and Lane (eds.), Cold Spring 1o Harbor Laboratory Press, 1988, which are also incorporated herein by reference).
Briefly, an animal is injected with a form of CD40 suitable for generating an immune response against CD40. The animal may be reimmunized as needed until levels of serum antibody to CD40 have reached a plateau, then be given a final boost of soluble CD40, and three to four days later sacrificed. Organs which contain large numbers of B
cells such as the spleen and lymph nodes are harvested and disrupted into a single cell suspension by passing the organs through a mesh screen or by rupturing the spleen or lymph node membranes which encapsulate the cells.
Alternatively, suitable cells for preparing monoclonal antibodies are obtained through the use of in vitro immunization techniques. Briefly, an animal is sacrificed and the spleen and lymph node cells are removed. A single cell suspension is prepared, and the cells are placed into a culture which contains a form of CD40, which is suitable for generating an immune response as described above. Subsequently, the lymphocytes are harvested and fused as described below.
Cells which are obtained through the use of in vitro immunization or fmm an immunized animal as described above may be immortalized by transfection with a virus.
For example, the Epstein Barr virus (EBV; see Glasky and Reading, Hybridoma 8(4):377-389, 1989) can transform human B cells. Alternatively, the harvested spleen and/or lymph node cell suspensions are fused with a suitable myeloma cell in order to create a "hybridoma" which secretes monoclonal antibody. Suitable myeloma lines are preferably 3o defective in the construction or expression of antibodies, and are additionally syngeneic with the cells from the immunized animal. Many such myeloma cell lines are well known in the art and may be obtained from sources such as the American Type Culture Collection (ATCC), Rockville, Maryland (see Catalogue of Cell Lines &
Hybridomas, 6th ed., ATCC, 1988).
CI?40 Lieand Activated CD4+ T cells express high levels of a ligand for CL140 (CD40L).
Human CD40L, a membrane-bound glycoprotein, was cloned from peripheral blood T-cells as described in Spriggs et al., J. Exp. Med 176:1543 (1992), and in United States Patent Application number 07/969,703, filed October 23, 1992, the disclosure of which is 1o incorporated by reference herein. The cloning of marine CD40L is described in Armitage et al., Nature 357:80, 1992. CD40L induces B-cell proliferation in the absence of any co-stimulus, and can also induce production of immunoglobulins in the presence of cytokines. In addition, CD40 ligand-transfected cells can stimulate monocytes to become tumoricidal (Alderson et al., J. Exp. Med 178:669, 1993).
CD40L is a type II membrane polypeptide having an extracellular region at its C-terminus, a transmembrane region and an intracellular region at its N-terminus. Soluble human CD44L comprises an extracellular region of CD40L (amino acid 47 to amino acid 261 ) or a fragment thereof that binds CD40 and tranduces a signal thereby.

biological activity is mediated by binding of the extracellular region of CD40L with 2o CD40, and includes B cell proliferation and induction of antibody secretion (including IgE secretion).
USSN 08/477,733 and USSN 08/484,624 describe the preparation of various soluble, oligomeric forms of CD40L, including a soluble CD40IJFc fusion protein referred to as CD44IJFC2. CD40IJFC2 contains an eight amino acid hydmphilic sequence described by Hopp et al. (Hopp et al., BiolTechnology 6:1204,1988;
referred to as Flag'), an IgG, Fc domain, a linker sequence (described in U.S. Patent 5,073,627), and the extracellular region of human CD40L. Also described is a soluble CD40L
fusion protein referred to as trimeric CD40L., which contains a 33 amino acid sequence referred to as a "leucine zipper," the eight amino acid hydrophilic sequence described by Hopp et 3o al. (supra), followed by the extracellular region of human CD44L. Both oligomeric forms of CD40L induce human B cell proliferation in the absence of any co-stimuli, and (in conjunction with the appropriate cytokine) result in the production of IgG, IgE, IgA and IgM. These soluble, oligomeric forms of CD40L will be useful in the present inventive methods, as will other forms of CD40L that can be prepared using known methods of preparing recombinant proteins.
WO 99132138 p~~sgg~'~
Additional CD40 Bindins P
Binding proteins may also be constructed utilizing recombinant DNA techniques to incorporate the variable regions of a gene which encodcs an antibody to CD40. (see James W. Larrick et al., "Polymerise Chain Reaction Using Mixed Primers:
Cloning of Human Monoclonal Antibody Variable Region Genes Prom Single Hybridoma Cells,"
Biotechnology 7:934-938, September 1989; Reichmann et al., "Reshaping Human Antibodies for Therapy," Nature 332:323-327, 1988; Roberts et al., "Generation of an Antibody with Enhanced Affinity and Specificity for its Antigen by Protein Engineering,"
. Nature 328:731-734, 1987; Verhoeyen et al., "Reshaping Human Antibodies:
Grafting an Antilysozyme Activity," Science 239:1534-1536, 1988; Chaudhary et al., "A
Roc;ombinant Immunotoxin Consisting of Two Antibody Variable Domains Fused to Pseudomonas Exotoxin," Nature 339:394-397, 1989).
Briefly, DNA encoding the antigen-binding site (or CD40 binding domain;
variable region) of a CD40 mAb is isolated, amplified, and linked to DNA
encoding another protein, for example a human IgG (see Verhoeyen et al., supra; see also 2o Reichmann et al., supra). Alternatively, the antigen-binding site (variable region) may be either linked to, or inserted into, another completely different protein (see Chaudhary et al., supra), resulting in a new protein with antigen-binding sites of the antibody as well as the functional activity of the completely different protein.
Furthermore, DNA sequences which encode smaller portions of the antibody or variable regions which specifically bind to mxunmalian CD40 may also be utilized within the context of the present invention. Similarly, the CD40 binding region (extracellular domain) of a CD40 ligand may be used to pncpare other CD40 binding proteins.
DNA
sequences that encode proteins or peptides that form oligomers will be particularly useful in preparation of CD40 binding proteins comprising an antigen binding domain of CD40 antibody, or an extracellular domain of a CD40 ligand. Certain of such oligomer-foaming proteins are disclosed in U.S.S.N. 07/969,703; additional, useful oligomer-forming proteins are also disclosed in U.S.S.N. 08/107,353, Hled August 13, 1993, and in U.S.S.N. 08/145,830, filed September 29, 1993.
Once suitable antibodies or binding proteins have been obtained, they may be isolated or purified by many techniques well known to those of ordinary skill in the art (see Antibodies: A Laboratory Manual, Harlow and Lane (eds.), Cold Spring Harbor 8 PCT/US98J2700s Laboratory Press, 1988). Suitable techniques include peptide or pmtein affinity columns, HPLC or RP-HPLC, purification on protein A or protein G columns, or any combination of these techniques. Recombinant CD40 binding proteins can be prepared according to standard methods, and tested for binding specificity to the CD40 utilizing assays known in the art, including for example ELISA, ABC, or dot blot assays, as well by bioactivity 1o assays such as those described for CD40 mAb.
In vitro and in vivo models Marine models of many infectious human diseases are known in the art. For example, Sher (Imm. Rev. 127:183-204, 1992), discusses marine models of several ~5 different human diseases, including acquired immunodeficiency syndrome (AIDS), toxoplasmosis, leishmaniasis, trypanosomiasis, and shistosomiasis. Nathan (in:
Mechanisms of Host Resistance to Infectious Agents, Tumors, and Allografts, R.M.
Steinman and R.J. North, eds., Rockefeller University Press, New York, pp.165-184, 1986) also reviews the use of mice in the study of various human diseases, and further 20 presents results of studies performed in humans that confirm results first observed in marine models.
Other species also provide useful animal models relevant to HIV infection. For example, Wyand (AIDS Res. and Human Retroviruses 8:349; 1992) discusses the use of SIV-infected Rhesus monkeys for the preclinical evaluation of AIDS drugs and vaccines.
25 Simian and feline models (Gardner, Antiviral Res. 15:267; 1991; Stahl-Hennig et al., AIDS 4:611; 1990) and marine moils (Ruprecht ef al., Cancer Res. 50:5618s;
1990) have been proposed for evaluating anti-retmviral therapy.
3o Activated macrophages ingest (phagocytose) microbes, produce and release highly reactive intracellular oxygen species, and secrete various cytokines that upregulate immune and inflammatory responses of the ma~nal to the microbe or microbes.
Activation of macrophages is confirmed in vitro by various moans involving measuring one or more of these activities.
35 One of the primary functions of peripheral blood monocytes is to regulate an immune or inflammatory response by synthesis and secretion of an array of biologically WO 99/32138 p~.N~'~
active molecules including enzymes, plasma proteins, cytokines and chemokines.
Activated macrophages produce and secrete various cytokines and chemokines, including Interieukin-6 (IL,-6), Interleukin-1 a and B (IL-la, IL-1B), Tbmor Necrosis Factor a, (TNF-a), Interleukin-8 (IL,..B), Macrophage Inhibitory Peptlde-la (MIP-la), Macrophage Inhibitory Peptide-1B (MIP-18), Interleukin-12 (11,-12) and growth regulatory protein (GRO). These molecules have broad immunoregulatory properties, and are useful in modulating an immune or inflammatory response.
Monocytes/macrophages are believed to be a major target of HIV-1 in vivo, and are thought to play an important role in the persistence of infection, serving as a viral reservoir. Immature monocytes in the blood differentiate and infiltrate tissues as more differentiated macrophages. In culture, blood-derived monocytes mimic this differentiation, enlarging and expressing various enzymes and cell-surface antigens characteristic of macrophages (Kaplan and Gaudernack, J. Fxp. Med. 156:1101;
1982).
Correlating with the differentiation of monocytes/macrophages is the differential expression of chemokine receptors. Freshly isolated monocytes express low levels of 2o CCRS mRNA that increase after in vitro differentiation. The increase in the expression of CCRS correlates with susceptibility to infection by macrophage-tropic (M-tropic) strains of HIV-1.
Dendritic cells (DC) are often referned to as professional antigen presenting cells;
as such, they play a critical role in the development of an immune response.
DC express CD40, and are known to be activated for antigen presentation by binding to CD40 ligand or agonistic CD40 antibodies. These cells are also thought to play a mle in HIV infection and in developing an anti-HIV immune response. Similar to monocytes/macrophages, DC may also serve as reservoirs of virus, and may potentiate the infection of T cells by HIV. Various methods for isolation of DC are known in the art, including purification 3o from peripheral blood by elutriation or affinity purification using monoclonal antibodies, isolation from cord blood, or from other DC-rich organs such as spleen, followed by growth under appropriate culture conditions.
Administration of CD40 bin ~ng nrotein~
The present invention provides methods of using therapeutic compositions comprising an effective amount of a CD40 binding protein and a suitable diluent and WO 99I3Z138 PCTNS98I2'f005 carrier, and methods for reducing susceptibility to infection by retrnviruses, including HIV. The use of CD40 binding proteins in conjunction with soluble cytokine receptors or cytokines, or other immunoregulatory molecules is also contemplated. For example, CD40 binding proteins can be used in conjunction with factors that are known to activate monocytes/macrophages, such as granulocyte-macrophage colony stimulating factor (GM-CSF), interferon-gamma (IFN-y), fusion proteins comprising GM-CSF such as those described in U.S. patent 5,073,627, and Interleukins 2 and 15. The CD40 binding proteins and the factors) can either be combined in suitable solution, or can be administered separately.
For therapeutic use, purified CD4U binding protein is administered to a patient, preferably a human, for ant in a manner appropriate to the indication. Thus, for example, CD40 binding protein compositions administered to reduce susceptibility to retrovirus infection can be given by bolus injection, continuous infusion, sustained release from implants, or other suitable technique. Typically, a therapeutic agent will be administered in the form of a composition comprising purified C1744 binding protein in 2o conjunction with physiologically acceptable carriers, excipients or diluents. Such carriers will be nontoxic to recipients at the dosages and concentrations employed.
Ordinarily, the preparation of such CD40 binding protein compositions entails combining the CD44 binding protein with buffers, antioxidants such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, amino acids, carbohydrates including glucose, sucrose or dextrins, chelating agents such as EDTA, glutathione and other stabilizers and excipients. Neutral buffered saline or saline mixed with conspecific serum albumin are exemplary appropriate diluents. Preferably, product is formulated as a lyophilizate using appropriate excipient solutions (e.g., sucrose) as diluents.
3o Appropriate dosages can be determined in trials, first in an appropriate animal model, and subsequently in the species to be treated. The amount and frequency of administration will depend, of course, on such factors as the nature and severity of the indication being treated, the desired response, the condition of the individual being treated, and so forth. Typically, therapeutically effective dosages of CD40 binding proteins will be in the range of from about 0.01 to about 1 mg/kg body weight.

WO 99/32138 p~N~pps The relevant disclosures of all references cited herein are specifically incorporated by reference. The following examples are intended to illustrate particular embodiments, and not limit the scope, of the invention.
Example 1 This example describes the preparation of cells used to determine the effects of soluble, oligomeric CD40 ligand (CD40L) on HIV replication. Monocytes were isolated from fresh peripheral blood mononuclear cells (PMBC) by adherence to plastic at 37°C.
Following one hour of culture, the adherent cells were washed extensively with medium and then removed from the flask by gentle scraping. Residual T- and B-lymphocytes were further depleted using anti-CD2 and anti-CD19 coated beads (Dynal Inc.).
These monocytes were typically 95~n CD14 positive as assayed by flow cytometry.
Mature macrophages were derived by culturing purified monocytes 7 days in RPMI 1640 containing 1096 fetal calf serum (FCS) in 5°~n COz incubator at 37°C with or without GM-2o CSF. At this time, 95°~n of the cells had become enlarged or spindle shaped with extended processes.
For RNA extraction and RT-PCR analysis of chemokine receptors of freshly isolated monocytes, cells were further purified using immunomagnetic microbeads conjugated with monoclonal anti-CD14 antibody (MACS Magnetic Cell Sorting Kit, Miltenyi Biotec Inc.). Monocyte purity was assessed by staining with anti-Cb 14 and by forward and side scatter measurement on flow cytometry. By this analysis the cell populations appeared to contain >99~v monocytes.
Example 2 This example describes an immunofluorescence assay for analyzing cell purity and the prescnce or absence of selected cell surface markers.
Monocytes/macrophages were dislodged from plates by treatment with PBS/O.SmM EDTA and incubated at room temperature for 15 minutes with PBS/4~v Human AB Serum to block Fc receptors.
The cells were then incubated for 15 minutes on ice in the presence of an appropriate dilution (in PBS containing 296 Human AB serum) of the following monoclonal antibodies wo ~r~zi3s pcrnrs9sr~~oos (mAb): anti-CD4 (I,eu-3A, Becton Dickinson); anti-CD14 (LeuM3, Becton Dickinson);
anti-CXCR4 (1265, kindly supplied by Dr. J. Hoxie, University of Pennsylvania); anti-CCRS (2D7 and 2F9, kindly supplied by Dr. C.R. MacKay, LeukoSite, Inc.).
Reactivity was compared to an isotype-matched control mAb (Zymed).
After three washes with cold PBS, the cells were incubated for 15 minutes on ice 1o with 0.1 ml of 1:50 dilution of goat anti-mouse IgG (H+L) F(ab')2 labeled with phycoerythrin (PE) (Boehringer Mannheim). After three additional washes with PBS, cells were resuspended in PBS containing 496 formaldehyde and then analyzed by FACS
on a Becton Dickinson FACSsort. For each deternunation 10,000 cells were analyzed.
Fluorescence was analyze by using the CellQuest software (Becton Dickinson).
To evaluate the level of nonspecific binding of goat anti-mouse IgG to monocytes-macrophages, cells were incubated with an isotype matched IgG control mAb before adding the secondary PFrconjugated antibody and processed as indicated above.
A marked decrease was observed in the expression of the chemokine roceptor CXCR4 and CD4 after 24 hours of culture, and by day 7 of culture, CXCR4 and 2o were undetectable. This finding was reproduced in cells from at least five different donors. Cells of some donors maintained expression of CXCR4, together with CCRS and CD4, probably due to the culture conditions, cell type or differentiation stage of monocytes/macrophages.
Example 3 This example describes RNA-PCR of chemokine receptor mRNA from cells isolated as described previously. Total cellular RNA was prepared using Triazol (GibcoJBRL), treated with RNase-free DNase (Boehringer-Mannheim) and used as a 3o template in RT-PCR. RNA was reverse transcribed in a 20 Etl inaction containing 1 ltg of total RNA, 1 pg oligo-dT, 200U Superscript reverse transcriptase (Gibco/BRL) and 0.5 mM of each dATP, dCTP, dGTP, dTTP. After incubating at 37°C one hour, 1:10 of the cDNA product was amplified in a 20 E,~l of reaction containing 0.1 pg of each primer hybridizing to the 5'- and 3'-ends of the chemokine receptors (CCR1-5 and CXCR4) or to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and lU of a Taq/Pwo polymerase mixture (Boehringer Mannheim).

WO 99/32138 PCTNS9$137005 CCRs were amplified by denaturing at 94°C, followed by a 30 cycles (94°C, 40 s;
60°C 40 s; 72°, 1 min). To control for contamination of the cellular RNA with genomic DNA, control cDNA reactions in which reverse transcriptaae was omitted were prepared in parallel. These were uniformly negative. The PCR products were separated by electrophoresis through 1 96 agarose. To test for the linearity of amplification, a 10-fold 1o dilution series, starting at lpg of chemolcine receptor plasmid DNA was amplified under conditions identical to those described above.
The sequences for the primers used are as follows: ~~ 5' CCA TGG AGA
AGG CTC GGG, 3' CAA AGT TGT CAT GGA TGA CC; CCR 11 S' GCC CAG AAA
CAA AGA CTT CAC GG, 3' GGA ATC CTG GGG AAC ATA GAA C; ~$~$ 5' ACG CAT TTC CCC AGT ACA TC, 3' TGT GAT TCA AAC GAC ATC AT;
5' TGA GAC AAG CCA CAA GCT G, 3' CTG AAT GCG TGA GCC CTT TCG TC;
5' TTC TAT CAC AGG GAG AAG TG, 3' ACT GGA AGT TTG AAG GAC
TGT T; CCR4 5' GCA AGC TGC TTC TGG TTG GGC CCA G, 3' GAA TGT GGA
AAA GTT CAT TGA C; CCRS S' GGT GGA ACA AGA TGG ATT AT, 3' ATG TGC
2o ACA ACT CTG ACT G; CXCR4_ 5' AGC GAG GTG GAC ATT CAT C, 3' ACG TGA
TTC ACT ACA GCT C.
The CXCR4 mRNA levels, although still high in cells after 24 hours of cultivation, decreased upon in vitro differentiation. In contrast, the CCRS
mRNA levels, barely detectable in freshly isolated monocytes, increased after in vitro differentiation, consistent with the higher infectability of these cells by M-tropic HIV-1 isolates.
CCR2A, CCR2B and CCR3 were up-regulated following 24 hours adhesion to plastic;
mRNA levels for these chcmokine receptors remained high until day 3, at which time they dropped dramatically(CCR3 mRNA was still detectable). In contrast, CCRl is constitutively expressed in both freshly isolated and cultured monocytes, while CCR4 is 3o not. These results suggest that CXCR4 and CCRS receptors are differently regulated during macrophage differentiation. Thus, CCRS mRNA and pmtein levels increase upon cultivation, allowing only the M-tropic strains of HIV-1 to enter these cells.

WO 99/32138 PCTNS98n7005 Example 4 This example describes the preparation of luciferase reporter viruses and an infecdvity assay designed to measure the ability of the viruses to infect cells. NL4-3-Luc-R-E- virus stocks pseudotyped by various Envs are generated by transfecting 293T cells to as described previously (Connor et al., Virology 206:93b; 1995) with 10 Ng each of NL4-3-Luc-R-E- and pcDNA-I/AMP-based expression vectors (Invitrogen) encoding HIV-JRFL, ADA, HXB2 or amphotropic MLV {A-MLV) Env. Virus-containing supernatants are collected 48 hours post-transfection and frozen at -70°. Viruses are quantified by p24 °'~ ELISA.
For single cycle infections with NL-Luc viruses pseudotyped with different Envs, 1X10' cells in 24-well plates, stimulated as described for individual experiments, are infected for four hours with 100 ng of p24 ~ of virus. This amount of virus is equivalent to 5-7 x10' TCID~ (determined by limiting dilution analysis of the virus stocks on activated PBMC) corresponding to an MOI of about 0.4.. After the four hour period, cells 2o are washed again, and cultured for an additional eight days. At designated time points the cells are lysed in 200 Erl lysis buffer (Promega) and stored at -70°C.
Luciferase activity is determined in 20 pl of each lysate using commercially available reagents (Promega) in a Lumat LB 9501 luminometer.
In one such experiment, cells were stimulated with CD40L (300 ng/ml), CD40L
+ GM-CSF (300 ng/ml and 1,000 Ulml, respectively) or SDF-la (10 nM) for 7 days.
Luciferase activity was high for both the M-tropic and amphotropic HIV-1 reporter viruses in the absence of CD40L. However, in the presence of CD40L, the luciferase activity was lower for HIV-1 reporter viruses pseudotyped by HIV-1~, suggesting that CD40L suppresses HIV-1 entry by down regulating the mRNA and protein levels of 3o CCRS. In addition, the luciferase activity for the amphotropic reporter virus was also depressed, suggesting that CD40L treatment of macrophages/monocytes may also result in a post-entry block of replication of retroviruses.
In another experiment, monocytes were treated with GM-CSF (either 100 U/ml or 10 U/ml; Immunex Corporation, Seattle, WA), CD40L (100 ng/ml), or a combination of GM-CSF and CD40L. The cells were stimulated with GM-CSF for 72 hours, then with WO 99/32138 PCT/US98/2?OOS
CD40L for 48 hours, analyzed by FACS for expression of chemokine rxeptors, and subjected to infectivity assay. In addition, supernatant fluids were harvested and assayed for the presence of chemokines. Results of the infectivity assay are shown in Table 1 below.
Table 1: Effect of Cytokines on Entry and Replication of GM-CSF, 100 Ulml JRFL 4,451 A-MLV 11,818 No ENV 40 GM-CSF, 10 U/ml JRFI. 6,495 A-MGV 7,497 No ENV 15 CD40L JRFL 4,273 A-MLV 11,051 No ENV 21 GM-CSF,100 U +CD40L JRFL 267 No ENV 16 GM-CSF,10 U, + CD40L 1RFL 2,530 2s A-MLV 9,334 No ENV 15 "' Luciferase activity, in counts per second Moreover, as shown in Figure 1, the combination of CD40L and GM-CF induced 3o production of greater amounts of several chemokines than either cytokine alone. In addition, FACS analysis indicated that the chemokine receptor CCRS was down-regulated in cells tnrated with GM-CSF, as wells as those treated with CD44L.

WO 99I3Z138 p~/V'pps Example 5 Monocytes were obtained, and stimulated with two different preparations of 1o CD40L, in the presence or absence of a neutralizing monoclonal antibody to (M90; Y,mmunex Corporation, Seattle, WA), for seven days. The cells were then infected as previously described, and the effect of CD40L on infectivity assessed by luciferase assay. Results are shown in Figure 2. Both preparations of D44L inhibited replication of the 1RFL pseudotyped virus; the inhibition was reversed by the addition of neutralizing antibody to CD40L.
In addition, the cells were analyzed fox expression of various surface markers, including chemokine receptor CCRS. Both preparations caused a decrease in the expression of CCRS. These results indicate that CD40L may decrease the replication of retroviruses that use CCRS as a co-receptor for infection of macrophagesJmonocytes in 2o several ways: increase in chemokine production will result in a block of viral entry because the necessary co-receptors are not available for viral binding; down-regulation of the CCRS chemokine receptor further decreases the number of available co-recxptor molecules. In addition, CD~WL, alone or in combination with GM-CSF, may induce a post-entry block of replication, as shown by the decrease in. infectivity of the amphotropic marine retrovirus in previous Examples.
Example 6 Peripheral blood mononuclear cells were obtained, and stimulated with phytohemaglutinin (PHA) for 72 hours. The cells were then washed, and medium containing Interleukin-2, CD40L, or II,-2 + CD40L, was added and the cells were incubated for 24 or 48 hours. At these time points, the cells were infected with HIV-1 Luciferase pseudotyped with JRFL or A-MLV or no ENV as described above. After five days, the cells were harvested and a luciferase assay was performed. The results for 48 WO 99/32138 p~~'pp~
hour time point are shown in Table 2 below; similar results were observed for the 24 hour time point.
Table 2: Effect of Cytolcines on Entry and Replication of HIV-1 La~cifer~~ PaPedotvne Vir~~.s in PBM
JRFL IL-2 7,473 CD40L 1,237 A-MLV IL-2 43,66b CD40L 52,890 No ENV IL-2 38 II~2/CD44L 13 These results demonstrate that CD40L causes a reduction in JRFL entry, and that the combination of IL-2 and CD~4OL provides a powerful method of inhibiting entry and replication. Because IL-1S shares many activities with IL-2, similar results would also be expected from this combination of cytokines.
Example 7 This example demonstrates that CI~tOL has similar effects on chemolcine and chemokine receptor expression in dendritic cells (DC) to those observed for monocytes.
Peripheral blood mononuclear cells are obtained, and cultured for five to seven days in GM-CSF and IL-4. Both monocytic cells and DC (cultured in GM-CSF and IL-4) exhibit wo ~r~m3s ~.,vs9sr~~oos s high levels of CCRS. When CD40L is added to the culture for the final 24 to 48 hours, the levels of CCRS are significantly decreased. Moreover, CD44L-stimulated DC
also express high levels of the B-chemokines MTP-la, NaP-1B, and RANTES. CD40L also results in diminished levels of some strains of HIV (as measured by analyzing reverse transcriptase (RT) activity) in co-cultures of T cells and DC infected with the BAL strain of HIV. However, in T cell/DC co-cultures infected with the IIIB strain of HIV, CD40L
did not result in decreased levels of RT activity; CD40L stimulation appeared to result in slightly higher RT activity in these co-cultures.
Example 8 This example demonstrates that CD44L inhibits replication of simian immunodeficiency virus (SIV) in rhesus macaque cells. Peripheral blood mononuclear cells were obtained, and stimulated with CL140L, which induced proliferation in a dose-dependent fashion. Viral antigen production by SIVmac239-infected PBMCs was reduced by about 70~ (2712 t 719 pg/ml; p<0.05) in PBMCs activated in the presence of CD40L (50 pg/ml). RT-PCR of total RNA from the PBMCs showed a 50.496 reduction in the expression of SIV gag and a 22696 increase in the expression of Interleukin-16 (11.-16) mRNA. The viral inhibition was not due to increased secretion of IL-lb, as supernatant fluids from CD40L-stimulated and control cultures contained similar amounts of IL-16 (2b.4 t 2.5 versus 25.3 t 1.7 pg/ml, respectively). Thus, CD40L leads to diminished SIV replication in rhesus macaque cells in a manner that involves mRNA expression.

Claims (4)

We claim:
1. A method for decreasing the infectability of a cell that expresses a CCR5 chemokine receptor for a retrovirus that uses the CCR5 chemokine receptor as a co-receptor, comprising contacting the cell with an amount of a CD40 binding protein sufficient to decrease expression of the CCR5 chemokine receptor.
2. The method of claim 1, wherein the CD40 binding protein is a soluble, oligomeric CD40L.
3. The method of claim 1, wherein the cell is also contacted with a cytokine selected from the group consisting of granulocyte macrophage colony stimulating factor, interleukin-2, interleukin-15, and combinations thereof.
4. The method of claim 2, wherein the cell is also contacted with a cytokine selected from the group consisting of granulocyte macrophage colony stimulating factor, interleukin-2, interleukin-15, and combinations thereof.
CA002313805A 1997-12-19 1998-12-18 Method for reducing susceptibility to hiv infection Abandoned CA2313805A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6835597P 1997-12-19 1997-12-19
US60/068,355 1997-12-19
US9847498P 1998-08-31 1998-08-31
US60/098,474 1998-08-31
PCT/US1998/027005 WO1999032138A1 (en) 1997-12-19 1998-12-18 Method for reducing susceptibility to hiv infection

Publications (1)

Publication Number Publication Date
CA2313805A1 true CA2313805A1 (en) 1999-07-01

Family

ID=26748884

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002313805A Abandoned CA2313805A1 (en) 1997-12-19 1998-12-18 Method for reducing susceptibility to hiv infection

Country Status (6)

Country Link
EP (1) EP1059932A1 (en)
JP (1) JP2001526241A (en)
AU (1) AU2004199A (en)
CA (1) CA2313805A1 (en)
IL (1) IL136731A0 (en)
WO (1) WO1999032138A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US20040247563A1 (en) * 2000-11-02 2004-12-09 Lynch David H. Method of enhancing lymphocyte-mediated immune responses
US7175838B2 (en) 2001-08-23 2007-02-13 The United States Of America Represented By The Department Of Health And Human Services Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
EP2583678A3 (en) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
AU2006202318A1 (en) 2005-06-02 2006-12-21 Wing-Yee Chan The preparation of multipotent stem cells and the use thereof
EP2857038B1 (en) 2006-09-18 2019-04-10 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses
NZ585776A (en) 2007-10-30 2012-07-27 Univ Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
CA2704422C (en) 2007-11-01 2019-09-24 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
NO2525817T3 (en) 2010-01-21 2018-01-06
JP5746333B2 (en) 2010-06-09 2015-07-08 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー Vaccines and methods for reducing Campylobacter infection
WO2014127185A1 (en) 2013-02-14 2014-08-21 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
CA2906079C (en) 2013-03-15 2022-08-23 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
BR112018072592A2 (en) 2016-05-03 2019-04-16 The Board Of Trustees Of The University Of Arkansas yeast vaccine vector that includes immunostimulating and antigenic polypeptides, and methods of using them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1059095A (en) * 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
DE69433820T2 (en) * 1993-12-23 2005-06-23 Immunex Corp., Seattle USE OF SOLUBLE OLIGOMERIC CD40 LIGANDS OR MONOCLONAL ANTIBODIES FOR THE MANUFACTURE OF A MEDICINE FOR PREVENTING OR TREATING NEOPLASTIC DISEASES
DK0812206T3 (en) * 1995-03-01 2002-09-09 Immunex Corp Method of Stimulating an Immune Response

Also Published As

Publication number Publication date
AU2004199A (en) 1999-07-12
JP2001526241A (en) 2001-12-18
WO1999032138A1 (en) 1999-07-01
IL136731A0 (en) 2001-06-14
EP1059932A1 (en) 2000-12-20

Similar Documents

Publication Publication Date Title
Trinchieri et al. Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation
CA2087525C (en) Adoptive immunotherapy with interleukin-7
AU693526B2 (en) Immuno-stimulatory monoclonal antibodies
JP7004761B2 (en) Improved Cell Compositions and Methods for Cancer Treatment
CA2313805A1 (en) Method for reducing susceptibility to hiv infection
US6039684A (en) Non-lethal conditioning methods for the treatment of acquired immunodeficiency syndrome
Fujimiya et al. In vitro interleukin 12 activation of peripheral blood CD3 (+) CD56 (+) and CD3 (+) CD56 (-) gammadelta T cells from glioblastoma patients.
Kornbluth The emerging role of CD40 ligand in HIV infection
WO1995020605A9 (en) Immuno-stimulatory monoclonal antibodies
Nagumo et al. Synergistic augmentative effect of interleukin‐10 and CD27/CD70 interactions on B‐cell immunoglobulin synthesis
Levitt et al. Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.
WO2018229163A1 (en) Methods of activating v delta 2 negative gamma delta t cells
MXPA05007129A (en) Uses of mammalian cytokine; related reagents.
US6074635A (en) T cell activation
Nguyen et al. Interleukin (IL)-15 enhances antibody-dependent cellular cytotoxicity and natural killer activity in neonatal cells
WO2003038062A2 (en) Generation of use of tc1 and tc2 cells
Bettens et al. Lymphokine gene expression related to CD4 T cell subset (CD45R/CDw29) phenotype conversion
Yamane et al. Effective stimulation for IL-12 p35 mRNA accumulation and bioactive IL-12 production of antigen-presenting cells interacted with Th cells
Bertagnolli et al. IL-4-supported induction of cytolytic T lymphocytes requires IL-2 and IL-6
JP6963560B2 (en) Methods of T cell expansion and activation
US6319493B1 (en) Treatment of neoplastic disease with interleukin-10
WO2000009150A2 (en) Cytokine and cytokine receptor, agonist, antagonist and/or antibody combination for therapeutic use
US6022536A (en) Combined use of interleukin 10 and cyclosporin for immunosuppression therapy
WO1997005896A1 (en) Combined use of interleukin-10 and cyclosporin for immunosuppression therapy
Zambello et al. IL‐12 is involved in the activation of CD3+ granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued